Study wrapper · #839
Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.
Editor's note
This state-of-the-art narrative review maps the drug landscape for metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory form, MASH. Semaglutide is genuinely foregrounded: the authors note it has received conditional approval for MASH alongside resmetirom, and they position incretin-based therapies as a potential backbone of complication-centric obesity management. That gives the peptide real standing in the piece. But as a review it summarizes rather than tests, and it is candid that pharmacological therapy for MASH-related cirrhosis remains an unmet need — the approvals apply to earlier disease, not advanced fibrosis. For readers, the value is context: semaglutide's role in liver disease is now regulatory reality, not just trial signal, but it sits within a crowded and evolving field (FGF-21 analogues, resmetirom, other incretins) and is not a stand-alone answer. Weight this as a credible orientation to where semaglutide fits in MASH care, not as new efficacy data.
Plain-language abstract
This review summarizes the current drug options for the most common chronic liver disease worldwide — metabolic dysfunction-associated steatotic liver disease (MASLD), often called fatty liver disease — and its more serious inflammatory form (MASH), which can progress to scarring and liver cancer. Losing weight through diet and lifestyle is the foundation of care, but that is hard to sustain, so medications matter. The authors note that two drugs have received conditional approval for MASH: resmetirom (a liver-targeted thyroid-hormone-receptor drug) and semaglutide (a GLP-1 receptor agonist). They review the wider and fast-changing landscape, including newer incretin-based drugs and FGF-21 analogues, plus non-invasive tests used to pick treatments and track response. The authors caution that effective drug therapy for advanced, cirrhosis-stage MASH is still lacking, which makes finding the disease early important. Because this is a review, it gathers and interprets existing evidence rather than reporting a new trial, and it places semaglutide within a broader group of emerging therapies.